Felix Hoffmann, Wilhelm Roehl, Hans Andersag and Walter Kikuth, Gerhard Domagk, Otto Bayer, Hermann Schnell, Friedrich Bossert, Wulf Vater – researchers and scientists who made history. They were responsible for pioneering inventions that revolutionized medicine, chemistry and materials development: Aspirin™, Germanin™, Resochin™, sulfonamides, polyurethanes, Makrolon™ and Adalat™.
These outstanding scientists all had one thing in common: they established Bayer's reputation as an innovation company. Bayer retains a strong commitment to this tradition. The Group’s realignment enables us to focus on areas where innovation is the driving force: health care, nutrition and high-tech materials.
Innovation plays a major role in addressing the global challenges of providing health care and nutrition for the world’s growing population and conserving dwindling resources. It is a key driver of future growth at Bayer.
In 2012 a total of €3,013 million was spent on research and development. This was equivalent to 7.6 percent of sales. Special importance is placed on the targeted development of new p roducts that strengthen the core businesses. Mindful of its corporate growth objectives, Bayer works to continuously rejuvenate and expand its product portfolio and optimize its production processes.
Its research and development activities are closely aligned to market requirements and therefore subject to a continuous process of adjustment. The Group’s activities are supplemented by an international network of collaborations with leading universities, public-sector research institutes and partner companies that is being steadily expanded in line with our main areas of research and development. Through this pooling of expertise, Bayer aims to rapidly translate new ideas into successful products. These activities are also supported by systematic employee development in the company’s research and development units.
Learn more about the innovation company on a journey through the world of research in our scientific magazine research.